Competition Grows In Claudin18.2 As AstraZeneca Seals Antibody Conjugate Deal
Chasing Astellas In Gastric Cancer
Executive Summary
Already a major player in the field thanks to Enhertu, AstraZeneca is doubling down in gastric cancer with the new antibody-drug conjugate deal with China’s KYM Biosciences.
You may also be interested in...
Chinese ADC Developers Forge Domestic Alliances To Push R&D
To date, nine major pairs of antibody and payload-linker platform makers based in China are making a concerted approach for ADC research and development, research by Scrip reveals.
Moderna and CARsgen Look For Synergies In CAR-T And Cancer Vaccine Combo
While Astellas is closing in on the first Claudin18.2 antibody therapy cancer approval, CARsgen and Moderna aim to boost responses from a CAR-T approach.
Japan Zolbetuximab Filing Heats Up CLDN18.2 Competition
Astellas says its first approval filing globally for zolbetuximab - in Japan for gastric cancer - came faster than expected, as Scrip takes a look at the latest status of other CLDN18.2-targeting candidates in late clinical trials.